非瓣膜性心房颤动：阿哌沙班对患者预后的影响。
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes.
作者信息
Ioannou Adam, Tsappa Irene, Metaxa Sofia, Missouris Constantinos G
机构信息
Cardiology Department, Royal Free NHS Foundation Trust, London, UK.
Cardiology Department, Medical School, University of Cyprus, Nicosia, Cyprus.
出版信息
Patient Relat Outcome Meas. 2017 Nov 3;8:121-131. doi: 10.2147/PROM.S117549. eCollection 2017.
Abstract
Atrial fibrillation is the most common arrhythmia worldwide, and carries a significantly increased risk of thromboembolic stroke. Initially, vitamin K antagonists were used as stroke prophylaxis; but more recently, a group of drugs known as novel oral anticoagulants have been developed. Apixaban belongs to this group of drugs, and is a factor Xa inhibitor that has emerged as a popular pharmacological agent worldwide. In this review, we will provide an overview of the pivotal trials in the development of apixaban, while also critically evaluating the new emerging real-world data, and discussing the effectiveness, safety, economic viability and future prospects of apixaban and how it impacts on patient outcomes in those with non-valvular atrial fibrillation.
摘要
心房颤动是全球最常见的心律失常，具有显著增加的血栓栓塞性中风风险。最初，维生素K拮抗剂被用作中风预防药物；但最近，一类被称为新型口服抗凝剂的药物已被研发出来。阿哌沙班属于这类药物，是一种Xa因子抑制剂，已成为全球流行的药物。在本综述中，我们将概述阿哌沙班研发过程中的关键试验，同时严格评估新出现的真实世界数据，并讨论阿哌沙班的有效性、安全性、经济可行性和未来前景，以及它如何影响非瓣膜性心房颤动患者的预后。
相似文献
1
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes.非瓣膜性心房颤动：阿哌沙班对患者预后的影响。
Patient Relat Outcome Meas. 2017 Nov 3;8:121-131. doi: 10.2147/PROM.S117549. eCollection 2017.
2
Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.真实世界中阿哌沙班在房颤卒中预防中的应用：系统评价和荟萃分析。
Stroke. 2018 Jan;49(1):98-106. doi: 10.1161/STROKEAHA.117.018395. Epub 2017 Nov 22.
3
Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).在心房颤动转复后应用阿哌沙班的疗效和安全性：来自 ARISTOTLE 试验（阿哌沙班用于减少心房颤动中的中风和其他血栓栓塞事件）的见解。
J Am Coll Cardiol. 2014 Mar 25;63(11):1082-7. doi: 10.1016/j.jacc.2013.09.062. Epub 2013 Nov 6.
4
Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.新型口服抗凝药物在房颤卒中预防中的应用：重点关注阿哌沙班。
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7.
5
6
Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.基于真实世界证据的非维生素 K 拮抗剂口服抗凝药与维生素 K 拮抗剂口服抗凝药用于非瓣膜性心房颤动患者卒中预防的治疗需要人数。
J Med Econ. 2019 Aug;22(8):760-765. doi: 10.1080/13696998.2019.1606001. Epub 2019 May 3.
7
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
8
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.在体重处于极端范围的房颤患者中，阿哌沙班与华法林的疗效和安全性。
Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
9
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.阿哌沙班与华法林在伴有心房颤动和心脏瓣膜病患者中的比较：来自心房颤动患者阿哌沙班减少卒中和其他血栓栓塞事件（ARISTOTLE）试验的结果。
Circulation. 2015 Aug 25;132(8):624-32. doi: 10.1161/CIRCULATIONAHA.114.014807. Epub 2015 Jun 23.
10
Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.非瓣膜性心房颤动患者真实世界临床实践中阿哌沙班与华法林的有效性和安全性：76940 例患者的倾向性匹配分析。
Thromb Haemost. 2017 Jun 2;117(6):1072-1082. doi: 10.1160/TH17-01-0068. Epub 2017 Mar 16.
引用本文的文献
1
Incidence and Predictors of Clinical Outcomes in Real-Life Patients With Atrial Fibrillation Treated With Oral Factor Xa Inhibitors: The Follow-Up Results of the ANATOLIA-AF Study.口服Xa因子抑制剂治疗的心房颤动真实患者临床结局的发生率及预测因素：ANATOLIA-AF研究的随访结果
Clin Cardiol. 2025 Jan;48(1):e70088. doi: 10.1002/clc.70088.
2
Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation.真实世界心房颤动患者中阿哌沙班浓度变异性及其与临床结局的关系。
Sci Rep. 2021 Jul 6;11(1):13908. doi: 10.1038/s41598-021-93372-9.
3
Special Issue "Cardiovascular Genetics".心血管遗传学特刊。
Genes (Basel). 2021 Mar 26;12(4):479. doi: 10.3390/genes12040479.
4
Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: A systematic review.直接口服抗凝剂超说明书剂量对房颤患者临床结局的影响：一项系统评价
Br J Clin Pharmacol. 2020 Mar;86(3):533-547. doi: 10.1111/bcp.14127. Epub 2020 Feb 5.
5
Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation.心房颤动患者使用直接口服抗凝剂与苯丙香豆素相比的出血、缺血性卒中和死亡率的比较风险。
Eur J Clin Pharmacol. 2018 Oct;74(10):1317-1325. doi: 10.1007/s00228-018-2504-7. Epub 2018 Jun 16.
本文引用的文献
1
Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis.新型口服抗凝剂用于房颤患者胃肠道出血和颅内出血的风险分析：系统评价和网络荟萃分析。
J Zhejiang Univ Sci B. 2017 Jul;18(7):567-576. doi: 10.1631/jzus.B1600143.
2
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.非瓣膜性心房颤动且既往有卒中和短暂性脑缺血发作患者中应用阿哌沙班、达比加群和利伐沙班与华法林的有效性和安全性。
Stroke. 2017 Aug;48(8):2142-2149. doi: 10.1161/STROKEAHA.117.017474. Epub 2017 Jun 27.
3
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.口服抗凝剂治疗非瓣膜性心房颤动患者的大出血风险：真实世界观察性研究的系统评价
Curr Med Res Opin. 2017 Sep;33(9):1583-1594. doi: 10.1080/03007995.2017.1347090. Epub 2017 Jul 6.
4
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.在美国医疗保险人群中，与华法林相比，起始使用阿哌沙班、达比加群或利伐沙班的非瓣膜性心房颤动患者发生中风/全身性栓塞、大出血及相关费用的风险。
Curr Med Res Opin. 2017 Sep;33(9):1595-1604. doi: 10.1080/03007995.2017.1345729. Epub 2017 Jul 11.
5
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.阿哌沙班用于降低器械检测到的亚临床房颤患者血栓栓塞事件（ARTESiA）试验的原理与设计
Am Heart J. 2017 Jul;189:137-145. doi: 10.1016/j.ahj.2017.04.008. Epub 2017 Apr 24.
6
Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.伴有单一卒中危险因素的房颤患者中标准剂量非维生素 K 拮抗剂口服抗凝剂和华法林的有效性和安全性：一项全国性队列研究。
JAMA Cardiol. 2017 Aug 1;2(8):872-881. doi: 10.1001/jamacardio.2017.1883.
7
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.真实世界中开始接受口服抗凝治疗的非瓣膜性心房颤动患者的大出血风险及医疗保健经济结果。
J Med Econ. 2017 Sep;20(9):952-961. doi: 10.1080/13696998.2017.1341902. Epub 2017 Jun 22.
8
Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.房颤消融期间阿哌沙班不间断治疗与华法林相比的安全性和有效性
Am J Cardiol. 2017 Aug 1;120(3):404-407. doi: 10.1016/j.amjcard.2017.04.041. Epub 2017 May 10.
9
Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.非维生素 K 拮抗剂口服抗凝剂在伴有肾功能障碍的心房颤动患者中的剂量调整。
J Am Coll Cardiol. 2017 Jun 13;69(23):2779-2790. doi: 10.1016/j.jacc.2017.03.600.
10
Comparative Effectiveness and Safety of Apixaban and Vitamin K Antagonist Therapy in Patients With Nonvalvular Atrial Fibrillation Treated in Routine German Practice.阿哌沙班与维生素K拮抗剂疗法在德国常规医疗中治疗非瓣膜性心房颤动患者的疗效和安全性比较
Heart Lung Circ. 2018 Mar;27(3):390-393. doi: 10.1016/j.hlc.2017.04.002. Epub 2017 May 3.
Zotero 插件